Ask AI

Optimizing Management of HER2-Negative MBC: Experts Discuss the Now and Future Roles of TROP-2–Directed ADCs

Gain more insights into the clinical role of TROP-2–directed ADCs in the management of patients with HER2-negative metastatic breast cancer, and learn how to individualize treatment in the sequencing of these agents and optimal management of the associated adverse events through a certified on-demand webcast, expert commentary, and downloadable slides.

Share

Program Content

Events

  • Live Event Optimizing Management of HER2-Negative MBC
    Optimizing Management of HER2-Negative MBC: Experts Discuss the Now and Future Roles of TROP-2–Directed ADCs
    Congratulations: You achieved a completion on 04/09/2022

    You can enroll in the following live event(s) on this topic.

Activities

TROP 2 Directed ADCs for HER2neg MBC
Optimizing Management of HER2-Negative MBC: Experts Discuss the Now and Future Roles of TROP-2–Directed ADCs
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 27, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.